Abstract
The use of transition metal complexes as appropriate analogues to cisplatin and similar anticancer drugs nowadays is of utmost importance. The inertness of Pt(IV), Pd(II), and Rh(III) complexes and the choosing of convenient ligands could offer a possible advantage in comparison to Pt(II) complexes. These advantages could be attributed to the better anticancer activity and fewer possible side effects. In this paper, we have chosen three complexes of different transition metal ions, [(TLtBu)PdIICl]ClO4, [RhIII(LH2tBu)Cl3], and [PtIV(LH2tBu)Cl3]Cl (where TLtBu is 2,6-bis[(1,3-di-tert-butylimidazolin-2-imino)methyl]pyridine and LH2tBu is 2,6-bis(5-tert-butyl-1H-pyrazol-3-yl)pyridine), for biological tests. All three complexes exerted strong prooxidative and cytotoxic effects on the human colorectal colon cancer HCT-116 cell line. The Pd(II) complex showed the most significant effect, while the Rh(III) complex showed the least effect.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
